Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only

Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only

(1 条用户评价)

$1.00

Tirzepatide Injection (MOUNJARO) contains 40mg (4 doses of 10mg/0.6ml) per vial. Manufactured by Eli Lilly Italia S.p.A. Approved in China (HJ20255004). Intended for laboratory research only. Wholesale and retail supported.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
分类:

描述

Tirzepatide is a novel dual GIP and GLP-1 receptor agonist designed to regulate insulin secretion, appetite control, and glucose metabolism. It has gained attention as a next-generation metabolic compound used in obesity and type 2 diabetes research.

Mufengda (MOUNJARO) is a multi-dose injectable formulation, offering 4 x 10mg doses (total 40mg in 2.4ml) per vial. This structure makes it highly adaptable for varied research models in metabolic regulation, endocrinology, and obesity-related studies.

?? This product is strictly for laboratory research use only. Not approved for clinical or veterinary application.


Product Specifications

Parameter Details
Product Name Tirzepatide Injection (Mufengda/MOUNJARO)
Generic Name Tirzepatide
CAS Number 2023788-19-2
Molecular Formula C???H???N??O??
Molecular Weight ~4813 Da
Dosage Form Injection
Strength 40mg per 2.4ml (4 x 10mg/0.6ml doses)
Quantity 1 vial per box
Approval Number HJ20255004 (China NMPA)
Product Code 86978403001637
Manufacturer Eli Lilly Italia S.p.A.
Storage Conditions Refrigerate at 2–8°C; do not freeze
Intended Use Laboratory research only

Mechanism & Research Applications

Tirzepatide mimics the action of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual receptor agonism enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces food intake.

It is actively applied in research related to:

  • Obesity and metabolic syndrome models

  • Type 2 diabetes mellitus (T2DM) mechanisms

  • Insulin resistance and glycemic control studies

  • Appetite suppression and gut-brain signaling

  • GLP-1 and GIP pathway pharmacodynamics


Observed Effects in Research Models

In preclinical and in vitro models, tirzepatide has demonstrated:

  • Enhanced glucose-dependent insulin secretion

  • Decreased food intake and body weight

  • Lowered HbA1c and fasting plasma glucose

  • Synergistic effects with other metabolic regulators

These properties make it ideal for endocrinology, nutrient metabolism, and anti-obesity drug development studies.


Safety & Handling

  • Research Use Only: Not for human, diagnostic, or veterinary use

  • Storage: 2–8°C. Do not freeze. Use under sterile lab conditions

  • PPE: Gloves, safety glasses, and lab coat recommended

  • Disposal: Follow institutional biohazard and chemical disposal protocols


Research Use Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for clinical, therapeutic, diagnostic, or veterinary purposes. Handle with care in a certified research environment following institutional safety protocols.

其他信息

重量 1 公斤
尺寸 26 × 23 × 26 厘米

Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only 有 1 个评价

  1. Ahmet

    The package is intact, thank you, I will contact you if I need it

添加评价

您的邮箱地址不会被公开。 必填项已用 * 标注

Q1: Is Tirzepatide Injection (MOUNJARO) approved for human use?

No. This version is strictly designated for laboratory research use only. It is not authorized for therapeutic or diagnostic application.

Q2: How is the dosage structured in the vial?

Each vial contains 2.4ml with 40mg tirzepatide, designed to deliver four 10mg doses (0.6ml each) for flexible experimental dosing.

Q3: What is the primary mechanism studied with tirzepatide?

Tirzepatide acts as a dual GIP and GLP-1 receptor agonist, useful in researching glycemic regulation, energy balance, and appetite suppression pathways.

Q4: Can I order this product in bulk?

Yes. Both retail and wholesale orders are supported, and we provide international shipping with full documentation.

Q5: What makes Mufengda's formulation reliable for research?

The product from Eli Lilly Italia S.p.A., approved under HJ20255004, offers consistent quality and accurate dosing—ideal for labs researching tirzepatide injection, GLP-1 analogues, or anti-obesity mechanisms.


EMI Options

Select at least 2 products
to compare